Spectrum's Rolontis meets in second Phase III for chemotherapy-induced neutropenia

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said Rolontis eflapegrastim met the primary endpoint of non-inferiority to Neulasta pegfilgrastim in the Phase III RECOVER trial in

Read the full 235 word article

User Sign In